Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials
John W. Eikelboom, Hardi Mundl, John H. Alexander, Valeria Caso, Stuart J. Connolly, Rosa Coppolecchia, Martin Gebel, Robert G. Hart, Gerlind Holberg, Lars Keller, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Ashkan Shoamanesh, Miriam Tamm, Thomas Viethen, Ashraf Yassen, Marc P. Bonaca
Topics & Concepts
MedicinePlaceboAtrial fibrillationInternal medicineStroke (engine)ApixabanIncidence (geometry)Myocardial infarctionHemostasisAdverse effectGastroenterologyThrombosisWarfarinRivaroxabanEngineeringPhysicsMechanical engineeringOpticsAlternative medicinePathologyAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAntiplatelet Therapy and Cardiovascular Diseases